At the ESC Congress 2023 (25-28 August, Amsterdam, The Netherlands) novel findings were revealed in more than 3,750 abstracts and clinical cases presented by scientists from 86 countries. Here we highlight latest insights on targeting atherogenic lipoproteins, likely mediators of effects seen in REDUCE-IT, genetic causal links between remnant cholesterol and cardiovascular outcomes, elevated TG and cardiac damage in young adults, and updates on novel therapies under investigation.
Read the reports:
- Targeting the spectrum of atherogenic lipoproteins
- REDUCE-IT: Likely mediators of IPE effects on MACE
- Mendelian randomisation study links remnant cholesterol to CV events
- Increased TG linked to cardiac damage in young adults
- Phase 1 data on ARO-ANG3 support safety and lipid effects
- Preclinical data support APOC3 inhibitor, RBD5044, for TG lowering
Reportage by Jenny Bryan